RankAlpha logo
Back to Rankings

KLRS

Kalaris TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Expanded Phase 1a cohorts reportedly reinforced favorable structural, functional, pharmacokinetic and time-to-retreatment observations, while Phase 1b/2 dosing and improved manufacturing provide tangible development progress [#SEC-8K-2026-08-11]. Cash runway is expected to extend through the principal preliminary-data milestone.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Cash declined from $118.0 million at December 31, 2025 to $93.5 million at June 30, 2026, reflecting operating cash use; continued development may require dilutive financing [#SEC-8K-2026-08-11].
Momentum
74
Value
59
Sentiment
78
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.50 · Bull $7.00 · Bear $1.50Analysis 2026-09-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-11 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-11

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $18.71
Why
Momentum74 · Δ7d -
Value59 · Δ7d 0.0
Sentiment78 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Sentiment remains the lead driver in the composite.

Contradictions & invalidation

  • • Cash declined from $118.0 million at December 31, 2025 to $93.5 million at June 30, 2026, reflecting operating cash use; continued development may require dilutive financing [#SEC-8K-2026-08-11].
  • • Dose selection, enrollment, manufacturing or regulatory execution could delay the preliminary readout or potential Phase 3 program.
  • • KLRS remains an early-stage, single-program-sensitive biotechnology investment.

Catalyst clock

2027-06-30

TH103 Phase 1b/2 preliminary data in 1H 2027 [#SEC-8K-2026-08-11]

Lead driver: Sentiment · See AI snapshot
Momentum
74
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.0
Sentiment
78
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 74.5 / Value 58.6 / Sentiment 78.0

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-11. Scenario method

B+
Bull case
25%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$86.49M
Beta
-0.10
Shares Out
23.81M
P/E (TTM) · Derived
-1.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.76
Rev YoY
-100.0%
EPS YoY
-20.3%
Gross Margin
-
Op Margin
-
Net Debt
-$116.53M
Current Ratio
10.92
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data